TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with the diagnosis of rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis receiving biosimilar etanercept (either 25 mg or 50 mg) for their medical condition.~Exclusion Criteria:~* No strict exclusion criteria were applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autoimmune Arthritis (Type: None): Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Treated with oral anti-diabetic (OAD) drugs for at least 3 months~* Treated with one or more OAD and in moderate to poor glycemic control~* Body Mass Index (BMI) less than or equal to 45.0 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last three months prior to the trial except due to intercurrent illness, at the discretion of the Investigator~* Any serious medical condition~* Treatment with any drug that could interfere with glucose level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patients should be indicated for a cystoscopic examination for suspected or verified papillary bladder cancer and fulfill one or more of the following criteria:~* Patients with more than one initial bladder tumor confirmed on an outpatient cystoscopy.~* Patients having recurrence within 12 months confirmed on an outpatient cystoscopy~* Patients with more than one papillary lesion at recurrence independently of the time of the recurrence confirmed on an outpatient cystoscopy~Exclusion Criteria:~* Patients with known tumors in the prostatic urethra or distal urethra~* Gross hematuria. (Note: Gross hematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy).~* Patient with porphyria.~* Known allergy to hexyl aminolevulinate hydrochloride or a similar compound.~* Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.~* Pregnant or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter).~* Patients who have received BCG or chemotherapy within three months prior to the initial cystoscopy/TURB, except for a single dose of chemotherapy for prevention of seeding after resection.~* Conditions associated with a risk of poor protocol compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard White Light Cystoscopy (Type: ACTIVE_COMPARATOR): None
- Standard White Light and Hexvix Fluorescence Cystoscopy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 \<85 years~* Patient is currently treated with an ACEI~* Patient must have acute angioedema attack caused by an ACEI~* Treatment should be administrated within 10 hrs after onset by an ACEI~* Patient with angioedema of head and /or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx)~* At least one moderate to severe severe angioedema symptom as assessed by the investigator, requiring a medical intervention~* Signed written Informed Consent Form~Exclusion Criteria:~* Diagnosis of angioedema that was not caused by ACEI: e.g. hereditary angioedema (C1-INH deficiency), allergy, anaphylaxis, insect bite, trauma, infection, abscess, tumor, post-radiation or post-operative or processes related to salivary glands and others where it is unlikely that the ACEI is causing the angioedema~* Participation in a clinical trial of another investigational medicinal product (IMP) within 30 days~* Patients with acute urticaria~* Patients with a medical history of any angioedema before taking an ACEI~* Patients with an acute rash or hives in the face or somewhere else~* Unstable angina or acute myocardial infarction~* Acute heart failure~* Serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial~* Pregnancy and/or breast-feeding~* Mental condition rendering the patients, in the opinion of the investigator, unable to understand the nature, scope and possible consequences of the study;~* Unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for the follow-up visit, or unlikely to complete the study for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.~Body Mass Index (BMI) of 17.5 to 32.5 kg/m2.~Signed and dated informed consent document.~Exclusion Criteria:~* Evidence or history of clinically significant abnormalities~* Have baseline orthostatic hypotension~* Positive drug screen, excessive alcohol and tobacco use

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
- Treatment B (Type: EXPERIMENTAL): Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
- Treatment C (Type: EXPERIMENTAL): Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form)~* Subject-reported history of Drye Eye Disease (DED) in both eyes~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning pregnancy~* Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening~* Ocular/peri-ocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that are expected to be active during the study~* Ongoing ocular or systemic infection~* Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study~* Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or saline components~* Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOV03 4 times daily (QID) (Type: EXPERIMENTAL): Perfluorohexyloctance solution 4 times daily (QID)
- NOV03 2 times daily (BID) (Type: EXPERIMENTAL): Perfluorohexyloctance solution 2 times daily (BID)
- Placebo 4 times daily (QID) (Type: PLACEBO_COMPARATOR): Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
- Placebo 2 times daily (BID) (Type: PLACEBO_COMPARATOR): Saline solution (0.9% sodium chloride solution) 2 times daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A woman between, and including, 10 and 25 years of age at the time of the first vaccination.~* Written informed consent from the subject prior to enrolment.~* Subject must be free of obvious health problems.~* Subject must have negative urine pregnancy test.~Exclusion Criteria:~* Pregnant or breastfeeding.~* Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality.~* History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease.~* Previous vaccination against human papillomavirus (HPV).

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF as defined by clinical features of CF and a documented sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations~* Informed consent and verbal assent (as appropriate) has been provided by the subject's parent or legal guardian and the subject~* 6-18 years of age at enrolment~* Able to perform reproducible spirometry~* Clinically stable at enrolment~* Ability to comply with medication use, study visits and study procedures as judged by the site investigator~* FEV1 % predicted \> 70 % as calculated by the Wang reference equations~Exclusion Criteria:~* Respiratory culture positive for:~  * NTM within past year or AFB positive at screening (sputum only)~ * B. cepacia complex within past year or at screening~* Use of intravenous antibiotics or oral quinolones within 14 days of screening~* Investigational drug use within 30 days of screening~* History of alcohol, illicit drug or medication abuse within 1 year of screening~* Other major organ dysfunction excluding pancreatic dysfunction~* History of lung transplantation or currently on lung transplant list~* Physical findings at screening that would compromise the safety of the participant or the quality of the study data

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
- 2 (Type: OTHER): This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* A male or female child between 18 months and 4 years of age (up to but not including 5th birthday) at the time of first vaccination.~* Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits)~Exclusion criteria:~* Acute disease at the time of enrolment.~* Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.~* Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of range.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid.~* Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Previous participation in any other malaria vaccine trial.~* Simultaneous participation in any other clinical trial.~* Same sex twin.~* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 48 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): None
- Group B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a documented HIV 1 infection (by any of the local standard diagnostic methods, such as HIV PCR-DNA, ELISA or western blot (WB) test for HIV antibodies, etc.)~* Body weight from 10 kg to less than 20 kg at screening~* Participants currently on stable ART (anti retroviral therapy) for at least 12 weeks, who need to change their ARV regimen because it is currently failing, with a viral load of greater than 1000 copies/mL~* Screening genotype resistance test results showing less than 3 DRV resistance-associated mutations~* Parents or legal representative willing and able to give consent~Exclusion Criteria:~* Participants with presence of any currently active conditions included in the listing of WHO ( World Health Organisation) Clinical Stage 4 and participants with presence of a non-HIV encephalopathy~* Administration of any ARV (antiretroviral) or non-ARV investigational medication or investigational vaccine within 30 days prior to screening, except for those medications where dose recommendations for children are available~* Life expectancy less than 6 months, according to the judgment of the investigator~* Co-enrollment in other clinical and/or cohort trials without written permission of the Sponsor~* Participants with any active clinically significant disease (eg, tuberculosis \[TB\], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the subject's safety or outcome of the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Darunavir (DRV)+Ritonavir (rtv) (Type: EXPERIMENTAL): Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ulipristal Emergency Contraception Used Before or After Ovulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy women aged 18 years or above;~2. Regular menstrual cycles (every 21-35 days) within the past three cycles;~3. Requesting emergency contraception within 120 h of a single act of unprotected intercourse in the current menstrual cycle;~4. Willing to abstain from further acts of unprotected intercourse and;~5. Available for follow-up over the next 6 weeks~Exclusion Criteria:~1. Post-abortion or postpartum patients whose period had not yet returned~2. Regular use of prescription drugs before admission to the study and~3. Intercourse during the treatment cycle more than 120 h before admission into the study.~4. Found pregnant at the time of presentation~5. Breastfeeding women~6. Women who have been sterilized (or partner being sterilized) or have intrauterine contraceptive device in-situ~7. Uncertain about the date of the last menstrual period~8. Women who had used hormonal contraceptive in the current or past one cycle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-ovulatory (Type: None): Ulipristal acetate 30 mg single oral dose
- Post-ovulatory (Type: None): Ulipristal acetate 30 mg single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Continuous antiretroviral therapy \> 18 months, and consistent HIV-RNA\< 40 copies/mL more than 12 months;~* 18-65 years old;~* Male or female;~* Good adherence and promise to follow-up;~* Inform Consent signed;~* CD4 T cells less than 300/ul .~Exclusion Criteria:~* Active opportunistic infection (not stable within 4 weeks 2 weeks ) or AIDS-related carcinoma;~* Hemoglobin (HGB) \< 9 g/dl, white blood cell (WBC) \< 2000/ul, granulin (GRN) \< 1000 /ul, platelet (PLT) \< 75000 /ul, Cr \>1.5x ULN, ALT or AST or alkaline phosphatase (ALP) \>3x upper limit of normal (ULN), total bilirubin (TBIL) \>2x ULN, creatine kinase (CK) \> 2x ULN;~* Pregnant or breastfeeding woman or woman with pregnancy plan;~* Active drug-user;~* Severe neurological defects;~* Active alcohol abuse;~* Severe gastrointestinal ulcer .~* End-stage disease such as cirrhosis, chronic obstructive pulmonary disease, congestive heart failure, recent myocardial ischemia,tumor, etc Those who are undertaking steroids, immunomodulator, anti-inflammatory agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TwHF extract + cART (Type: EXPERIMENTAL): Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
- cART control (Type: OTHER): Continue current cART regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete